Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377049 | 0.98 | DUT (0.41) | DUT | |
| SCHEMBL30042679 | 0.98 | DUT (0.41) | DUT | |
| SCHEMBL16726889 | 0.98 | DUT (0.41) | DUT | |
| SCHEMBL29750295 | 0.89 | DUT (0.37) | DUT | |
| SCHEMBL29102792 | 0.82 | DUT (0.41) | DUT | |
| SCHEMBL64584 | 0.81 | DUT (0.30) | DUT | |
| SCHEMBL17739984 | 0.80 | DUT (0.39) | DUT | |
| SCHEMBL11580466 | 0.78 | DUT (0.42) | DUT | |
| SCHEMBL573170 | 0.77 | DUT (0.35) | DUT | |
| SCHEMBL2151853 | 0.77 | DUT (0.38) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4733299-A1 | SULFUR-CONTAINING FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Braegen Pharmaceutical Co., Ltd. (CN) | 2026-04-29 | — | — | EP | disclosed |
| CN-117603230-B | Tri-bicyclic compounds as JAK inhibitors and PHD inhibitors | 英矽智能科技(上海)有限公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2024240186-A1 | SULFUR-CONTAINING FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳博芮健制药有限公司 | 2024-11-28 | — | — | WO | disclosed |
| EP-3678700-B1 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | MERCK SHARP & DOHME LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2024-03-05 | — | — | US | disclosed |
| CN-117603230-A | Tri-bicyclic compounds as JAK inhibitors and PHD inhibitors | 英矽智能科技(上海)有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-20220378916-A1 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | MERCK SHARP & DOHME LLC (US) | 2022-12-01 | — | — | US | disclosed |
| US-20160317458-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| EP-3083579-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | US | disclosed |
| EP-2989086-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | Pierre Fabre Médicament (FR) | 2016-03-02 | — | — | EP | disclosed |
| WO-2015162293-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015095346-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014174060-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2014-10-30 | — | — | WO | disclosed |
| US-8198269-B2 | Fused aminodihydrothiazine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, BACE2, APP | DUT 4398/4885 |
| US-20160317458-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | SGMS1, PHOSPHO1, LIPA | DUT 4624/4885 |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | DUT 9/4885 |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | DUT 882/4885 |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | DUT 823/4885 |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | DUT 9/4885 |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | DUT 4655/4885 |
| US-20220378916-A1 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | CD274, PDCD1, JAK1 | DUT 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.